Thiazolidinedione analogues
First Claim
Patent Images
1. A method of treating hypertension comprising administering to a patient a pharmaceutical composition including a compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein;
R1 is hydrogen or an optionally substituted aliphatic;
R2 is hydrogen, halo, hydroxy, oxo, or optionally substituted aliphatic;
R3 is hydrogen, halo, or optionally substituted aliphatic; and
Ring A is a phenyl or a monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S, either of which is substituted with —
CH2—
R1 at any chemically feasible position on ring A.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to thiazolidinedione analogues that are useful for treating hypertension.
19 Citations
76 Claims
-
1. A method of treating hypertension comprising administering to a patient a pharmaceutical composition including a compound of formula I:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, halo, hydroxy, oxo, or optionally substituted aliphatic; R3 is hydrogen, halo, or optionally substituted aliphatic; and Ring A is a phenyl or a monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S, either of which is substituted with —
CH2—
R1 at any chemically feasible position on ring A.- View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
-
2. A method of treating hypertension comprising administering to a patient a pharmaceutical composition comprising a compound of formula III:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; R3 is hydrogen, halo, or optionally substituted aliphatic; and Ring A is a monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S that is substituted with —
CH2—
R1 at any chemically feasible position on ring A.
-
-
3. A method of treating hypertension comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a compound of formula IV:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
4. A method of treating hypertension comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a compound of formula V:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
5. A method of treating hypertension comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a compound of formula VI:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
26. A method of lowering lipids comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a statin and a compound of formula I:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, halo, hydroxy, oxo, or optionally substituted aliphatic; R3 is hydrogen, halo or optionally substituted aliphatic; and Ring A is a phenyl or a monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S, either of which is substituted with —
CH2—
R1 at any chemically feasible position on ring A.- View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
-
27. A method of lowering lipids comprising administering to a patient a pharmaceutical composition comprising a statin and a compound of formula III:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; R3 is hydrogen, halo, or optionally substituted aliphatic; and Ring A is a monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S that is substituted with —
CH2—
R1 at any chemically feasible position on ring A.
-
-
28. A method of lowering lipids comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a statin and a compound of formula IV:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
29. A method of lowering lipids comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a statin and a compound of formula V:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
30. A method of lowering lipids comprising administering to a patient a pharmaceutically acceptable dose of a pharmaceutical composition comprising a statin and a compound of formula VI:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
51. A pharmaceutical composition comprising a compound of formula I:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, halo, hydroxy, oxo, or optionally substituted aliphatic; R3 is hydrogen, halo or optionally substituted aliphatic; and Each ring A is a phenyl or a monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S, either of which is substituted with —
CH2—
R1 at any chemically feasible position on ring A.- View Dependent Claims (56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)
-
-
52. A pharmaceutical composition comprising a compound of formula III:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; R3 is hydrogen, halo, or optionally substituted aliphatic; and Ring A is an optionally substituted monocyclic heteroaryl having 1-3 heteroatoms selected from N, O, or S that is substituted with —
CH2—
R1 at any chemically feasible position on ring A.
-
-
53. A pharmaceutical composition comprising a compound of formula IV:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
54. A pharmaceutical composition comprising a compound of formula V:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
55. A pharmaceutical composition comprising a compound of formula VI:
-
or a pharmaceutically acceptable salt thereof, wherein; R1 is hydrogen or an optionally substituted aliphatic; R2 is hydrogen, hydroxy, or aliphatic optionally substituted with hydroxy; and R3 is hydrogen, halo, or optionally substituted aliphatic.
-
-
75. A pharmaceutical composition comprising a compound selected from
Compound No. 1 Compound No. 2 Compound No. 3 Compound No. 4 Compound No. 5 Compound No. 6 Compound No. 7 Compound No. 8 Compound No. 9 Compound No. 10 Compound No. 11 Compound No. 12 Compound No. 13
Specification